Biohackers, chew this.
Anti-aging fans have tried, including taking certain drugs out of marking in the hope that they will lead to a longer and healthier life.
A new study outside of Germany provides new tests that this approach can be worth it. Researchers at the Max Planck Institute for aging aging found that a combination of two cancer medicines extended the life of mice about 30%.
But the buyer takes care. One of the drugs, Rapamycin, has caused controversy over his safety and effectiveness in humans. Biohacking Buff, Bryan Johnson, 47, even admitted that he threw him from his regime.
Rapamicin is an immunosuppressive used to prevent organs’ rejection in patients with transplantation.
The pill was found in the new study to increase the life of the mouse between 15% and 20% on its own.
Rapamycin inhibits the MTOR track, which regulates main body functions such as protein synthesis, cell growth and “zombie” cell clearing that do not work properly, but refuse to die.
As it suppresses the immune system, a significant disadvantage of rapamycin is that it increases the risk of infections.
Other potential side effects include high levels of cholesterol and triglycerides in the blood, gastrointestinal problems, skin problems, headaches, fatigue and drug interactions.
Johnson had experimented with different doses of the drug for five years before he stopped taking it in September.
“ Despite the immense potential of pre-clinical essays, my team and I concluded that the advantages of rapamycin’s lifelong dosage do not justify strong side effects (intermittent skin infections/soft tissue, lipid abnormalities, glucose elevations and increased heart rate at rest), ” wrote Johnson in January.
Rapamycin, together with Trametinib, made wonders in the new study.
The traminib is used to treat certain types of low -grade melanoma and glioma, among other cancers. It interferes with the signals that say that cancer cells multiply.
Trameinib expanded the mouse from 5% to 10% alone, and it was even better with rapamycin.
“Traminib, especially in combination with rapamycin, is a good candidate who was tested in clinical trials as a GeroProtector,” said the author of the Sebastian Grönke studio.
“We hope that our results will be assumed by others and will be tested in humans. Our goal is to optimize the use of trametinib on animal models.”
Twice of rapamycin and trametinib influenced gene expression differently than each drug in itself.
Researchers found lower amounts of harmful inflammation in tissue and brain and cancer did not develop so quickly.
The findings were published this week in the journal Nature Aging.
“Although we do not expect a similar extension to the human life life we have found in mice, we hope that the drugs we research can help people stay healthy and free of illness for later life,” said Co -enior Linda Partridge.
“A more advanced research in humans in the coming years will help us to elucidate how these medicines can be useful to people and for whom they could benefit.”
#drugs #caused #mice #live #longer #Bryan #Johnson #warned #disadvantages
Image Source : nypost.com